This new companion to Hochberg et al.'s Rheumatology masterwork focuses on the momentous recent advances in our understanding of the genetics and immunology of psoriatic and reactive arthritis, and their implications for diagnosis and management. Leading international authorities explore new concepts in genetic and pathogenic mechanisms and early diagnosis; provide comprehensive, well-illustrated coverage of clinical features; evaluate the very latest therapeutic options, including biologics; and discuss clinical outcome measures. Examines the very latest pathogenic mechanisms and diagnostic criteria, providing the necessary tools for early diagnosis and monitoring of disease progression. Offers comprehensive coverage of the clinical manifestations of psoriatic and reactive arthritis, including a amini atlas' of color plates. Examines the pros and cons of the available therapeutic options, including the very latest biological as well as traditional therapies. Includes practical discussions of clinical outcome measures, delivering ongoing tools for assessment of function, disease activity, and quality of life.They should be started in a high dose (prednisone 30 to 40 mg/day) and tapered down rapidly according to clinical response. ... Prompt treatment of new genitourinary Chlamydia infections reduces relapses of CIA. ... The results showed that in the long term, lymecycline treatment did not change the natural history of the disease.30 A small double-blind ... morning stiffness and joint pain. 33 Overall, the question of whether or not antibiotics work for CIA has not been fully answered.
|Title||:||Psoriatic and Reactive Arthritis|
|Author||:||Christopher T. Ritchlin, Oliver FitzGerald|
|Publisher||:||Elsevier Health Sciences - 2007-06-25|